NO20006026L - Fremgangsmåter og blandinger for modulering av angiogenese ved bruk av tyrosin kinase SRC - Google Patents

Fremgangsmåter og blandinger for modulering av angiogenese ved bruk av tyrosin kinase SRC

Info

Publication number
NO20006026L
NO20006026L NO20006026A NO20006026A NO20006026L NO 20006026 L NO20006026 L NO 20006026L NO 20006026 A NO20006026 A NO 20006026A NO 20006026 A NO20006026 A NO 20006026A NO 20006026 L NO20006026 L NO 20006026L
Authority
NO
Norway
Prior art keywords
src protein
methods
nucleic acids
acids encoding
compositions
Prior art date
Application number
NO20006026A
Other languages
English (en)
Other versions
NO20006026D0 (no
NO327610B1 (no
Inventor
David A Cheresh
Brian Eliceiri
Pamela L Schwartzberg
Original Assignee
Scripps Research Inst
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Us Health filed Critical Scripps Research Inst
Publication of NO20006026D0 publication Critical patent/NO20006026D0/no
Publication of NO20006026L publication Critical patent/NO20006026L/no
Publication of NO327610B1 publication Critical patent/NO327610B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20006026A 1998-05-29 2000-11-28 Farmasoytisk sammensetning omfattende et aktivt Src-protein eller et oligonukleotid som koder for det samme samt anvendelser derav. NO327610B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8722098P 1998-05-29 1998-05-29
PCT/US1999/011780 WO1999061590A1 (en) 1998-05-29 1999-05-28 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src

Publications (3)

Publication Number Publication Date
NO20006026D0 NO20006026D0 (no) 2000-11-28
NO20006026L true NO20006026L (no) 2001-01-24
NO327610B1 NO327610B1 (no) 2009-08-31

Family

ID=22203825

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006026A NO327610B1 (no) 1998-05-29 2000-11-28 Farmasoytisk sammensetning omfattende et aktivt Src-protein eller et oligonukleotid som koder for det samme samt anvendelser derav.

Country Status (23)

Country Link
US (1) US7585841B2 (no)
EP (1) EP1082415B1 (no)
JP (1) JP4806487B2 (no)
KR (1) KR20010085261A (no)
CN (1) CN1304567C (no)
AT (1) ATE506073T1 (no)
AU (1) AU762955C (no)
BR (1) BR9910787A (no)
CA (1) CA2330025C (no)
CZ (1) CZ302918B6 (no)
DE (1) DE69943374D1 (no)
DK (1) DK1082415T3 (no)
ES (1) ES2361659T3 (no)
HU (1) HU227985B1 (no)
MX (1) MXPA00011821A (no)
NO (1) NO327610B1 (no)
PT (1) PT1082415E (no)
RU (1) RU2222342C2 (no)
SK (1) SK287330B6 (no)
TR (1) TR200100430T2 (no)
UA (1) UA75565C2 (no)
WO (1) WO1999061590A1 (no)
ZA (1) ZA200007321B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
US6685938B1 (en) * 1998-05-29 2004-02-03 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
ATE506073T1 (de) * 1998-05-29 2011-05-15 Scripps Research Inst Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
HU229628B1 (en) * 1999-12-22 2014-03-28 Scripps Research Inst Angiogenesis and vascular permeability modulators and inhibitors
US7485414B2 (en) * 2002-08-30 2009-02-03 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
CN103463621B (zh) * 2006-10-31 2016-01-06 托莱多大学 Src和Src家族激酶的Na+/K+-ATP酶特异性肽抑制剂/激活剂
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
BRPI1008955A2 (pt) 2009-03-13 2015-09-01 Abraxis Bioscience Llc Terapia de combinação com derivados de tiocolchicina.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7432496A (en) * 1995-10-13 1998-05-11 Regents Of The University Of Minnesota Consolidated ligands with increased affinities and methods of use thereof
US6335010B1 (en) * 1996-11-08 2002-01-01 University Of California At San Diego Gene therapy in coronary angioplasty and bypass
ATE506073T1 (de) * 1998-05-29 2011-05-15 Scripps Research Inst Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
GB2341182A (en) * 1998-09-01 2000-03-08 Yamanouchi Uk Ltd Protein comprising amino acid sequences having SH3 domain binding activity and nuclear localisation activity

Also Published As

Publication number Publication date
WO1999061590A9 (en) 2000-03-09
HU227985B1 (en) 2012-07-30
AU762955C (en) 2005-03-24
KR20010085261A (ko) 2001-09-07
US20060009412A1 (en) 2006-01-12
DE69943374D1 (de) 2011-06-01
TR200100430T2 (tr) 2002-05-21
ZA200007321B (en) 2002-03-08
HUP0102614A2 (hu) 2001-11-28
RU2222342C2 (ru) 2004-01-27
HUP0102614A3 (en) 2005-11-28
SK287330B6 (sk) 2010-07-07
EP1082415B1 (en) 2011-04-20
US7585841B2 (en) 2009-09-08
BR9910787A (pt) 2001-10-30
CA2330025C (en) 2009-03-17
NO20006026D0 (no) 2000-11-28
EP1082415A4 (en) 2003-07-09
ATE506073T1 (de) 2011-05-15
PT1082415E (pt) 2011-07-04
WO1999061590A1 (en) 1999-12-02
EP1082415A1 (en) 2001-03-14
ES2361659T3 (es) 2011-06-21
DK1082415T3 (da) 2011-06-14
CA2330025A1 (en) 1999-12-02
AU762955B2 (en) 2003-07-10
UA75565C2 (uk) 2006-05-15
AU4101399A (en) 1999-12-13
CN1319131A (zh) 2001-10-24
SK18112000A3 (sk) 2001-09-11
JP2002516344A (ja) 2002-06-04
CZ20004435A3 (en) 2001-06-13
CZ302918B6 (cs) 2012-01-18
MXPA00011821A (es) 2004-07-30
JP4806487B2 (ja) 2011-11-02
HK1041289A1 (en) 2002-07-05
NO327610B1 (no) 2009-08-31
CN1304567C (zh) 2007-03-14

Similar Documents

Publication Publication Date Title
DE69828408D1 (de) Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
AU2464601A (en) Tricyclic protein kinase inhibitors
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
WO1999036550A3 (en) Human protease molecules
DE60205776T2 (de) Indolinon-derivative als protein-kinasehemmer
DK1905457T3 (da) Farmaceutiske sammensætninger omfattende Src og/eller Yes samt anvendelse deraf
DK1082415T3 (da) Anvendelige fremgangsmåder til modulation af angioge-nese ved anvendelse af tyrosin kinase SRC
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
WO2001087287A3 (en) Use of pyrazole derivatives for treating infertility
MXPA02010759A (es) Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.
BR0013228A (pt) Método e composições utilizados para modulação de angiogenese usando proteìna quinase raf e ras
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE362768T1 (de) Prb2/p130 peptidinhibitoren der cdk2 kinaseaktivität
ATE395935T1 (de) An der oberfläche von karzinomzellen lokalisiertes colligin/hsp47
ATE364625T1 (de) Proteine aus yaba monkey tumor virus mit modulatorischer aktivität
DE60333747D1 (de) Dna-enzym zur hemmung von plasminogenaktivator-inhibitor-1
NO20023914L (no) Preparater for anvendelse for regulering av aktiviteten til parkingenet
WO2001012213A3 (en) Ttp-related zinc finger domains and methods of use

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees